Expertise in
45
conditions

Dr. Jatinder S. Pruthi

Gastroenterology
Office
1753 W Avenue J, 
Lancaster, CA 
Offers Telehealth
Expertise in
45
conditions
Office
1753 W Avenue J, 
Lancaster, CA 

Overview

Jatinder Pruthi is a Gastroenterologist practicing medicine in Lancaster, California.

Dr. Pruthi is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Hemorrhoids, Chronic Erosive Gastritis, Gastrectomy, and Gastrostomy.

He is actively involved in clinical research, participating in 15 clinical trials.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Hospital Affiliations

Palmdale Regional Medical Center
Ridgecrest Regional Hospital
Antelope Valley Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Office
1753 W Avenue J, Lancaster, CA 93534
Other Locations
United Valley Medical Consultants
44215 15th St W Ste 209, Lancaster, CA 93534

Additional Areas of Focus

Dr. Pruthi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared With Oral Vancomycin in Adults With Clostridioides Difficile Infection
A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared With Oral Vancomycin in Adults With Clostridioides Difficile Infection
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: CRS3123
Study Phase: Phase 2
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 With Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Enrollment Status: Completed
Publish Date: March 10, 2026
Intervention Type: Drug
Study Drug: CNP-104
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Combination product
Study Drug: AZ-010
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Expertise in
23
conditions
Dr. Norah A. Terrault
Gastroenterology
Referral may be required

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (44.2 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Norah Terrault is a Gastroenterologist practicing medicine in Los Angeles, California. Dr. Terrault is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Expertise in
42
conditions
Dr. James L. Buxbaum
Gastroenterology
Expertise in
42
conditions
Dr. James L. Buxbaum
Gastroenterology
Referral may be required

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (44.2 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Buxbaum is a Gastroenterologist practicing medicine in Los Angeles, California. Dr. Buxbaum is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Acute Pancreatitis, Hereditary Pancreatitis, Bile Duct Obstruction, Endoscopy, and Lithotripsy.

Expertise in
15
conditions
Dr. Mark A. Pimentel
Gastroenterology
Expertise in
15
conditions
Dr. Mark A. Pimentel
Gastroenterology
Referral may be required

Cedars-Sinai Gastrointestinal (Gi) Motility

8720 Beverly Blvd, 
West Hollywood, CA 
 (44.2 miles away)
310-423-6143
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Pimentel is a Gastroenterologist practicing medicine in West Hollywood, California. Dr. Pimentel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Irritable Bowel Syndrome (IBS), Small Bowel Bacterial Overgrowth, Diarrhea, Endoscopy, and Appendectomy.

Frequently Asked Questions about Dr. Jatinder S. Pruthi

How do I make an appointment with Dr. Jatinder S. Pruthi?

You can book an appointment with Dr. Jatinder S. Pruthi by calling their office at 661-945-7853. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jatinder S. Pruthi a top-rated expert for Gastroesophageal Reflux Disease (GERD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jatinder S. Pruthi is classified as an Distinguished expert for Gastroesophageal Reflux Disease (GERD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jatinder S. Pruthi specialize in?

While Dr. Jatinder S. Pruthi is a Gastroenterology, they have specific expertise in Gastroesophageal Reflux Disease (GERD), Hemorrhoids, and Chronic Erosive Gastritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Jatinder S. Pruthi accept my insurance?

Dr. Jatinder S. Pruthi accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 661-945-7853 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pruthi's expertise for a condition
ConditionClose
    View All 42 Advanced Conditions
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile